<DOC>
	<DOCNO>NCT01804296</DOCNO>
	<brief_summary>This research proposal aim good understand neurobiology depression adolescent repetitive transcranial magnetic stimulation ( rTMS ) may therapeutically impact brain function mood . This investigation also propose first study examine efficacy rTMS maintenance therapy adolescent meet clinical criterion follow acute rTMS treatment . The magnetic resonance ( MR ) spectroscopy pattern rTMS response analyze accord previously establish protocol .</brief_summary>
	<brief_title>rTMS Depressed Teens : A Sham-Controlled Trial , Part 2</brief_title>
	<detailed_description>Part 2 study aim : - Evaluate benefit daily , active , open-label rTMS Part 1 non-responders . - Evaluate benefit bi-weekly , active , open-label maintenance rTMS treatment Part 1 responder course 12 month post acute treatment . - Evaluate , proton magnetic resonance spectroscopy ( 1H-MRS ) 3 Tesla ( 3T ) , neurometabolic biomarkers begin end study phase . - Define regional specificity [ anterior cingulate ( AC ) leave dorsolateral prefrontal cortex ( L-DLPFC ) ] cerebral metabolite ( i.e . glutamate glutamine ) adolescent depression . - Study whether specific neurochemical resonance associate response , remission , and/or maintenance improvement clinical depressive symptom rTMS use treat adolescent depression .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Successful completion Part 1 study Diagnosis unipolar major depressive disorder , current major depressive episode , without psychotic feature Age least 12 less 22 year Ongoing , stable dose antidepressant therapy least 6 week include follow antidepressant ( dose range ) : Celexa ( citalopram hydrobromide ) 10 60mg Cymbalta ( duloxetine ) 40mg 120mg Desyrel ( trazodone HCl ) 12.5mg 150mg Effexor ( venlafaxine HCl ) 37.5mg 300mg Luvox ( fluvoxamine maleate ) 25mg 200mg Lexapro ( escitalopram oxalate ) 10mg 40mg Paxil ( paroxetine HCl ) 10mg 50mg Pristiq ( desvenlafaxine ) 50mg 100mg Prozac ( fluoxetine HCl ) 10mg 80mg Remeron ( mirtazapine ) 7.5mg 45mg Savella ( milnacipran HCl ) 25mg 200mg Zoloft ( sertraline HCl ) 25mg 200mg Subjects able attend study visit study site . Willing provide inform assent ( adolescent ) inform consent ( family ) Withdrew treatment study Part 1 Subjects currently stimulant , antipsychotic , bupropion tricyclic antidepressant medication . Prior vagus nerve stimulation ( VNS ) electroconvulsive therapy ( ECT ) Contraindication MRI Contraindication rTMS ( history neurological disorder seizure , increase intracranial pressure , brain surgery , head trauma loss consciousness &gt; 15 minute , history stroke , family history epilepsy , intracardiac line , Anticoagulant , immune suppressive and/or chemotherapy , receive therapy within 3 month enrollment study Unstable medication condition hematological infectious ( e.g. , human immunodeficiency virusHIV ) disorder , implant electronic device , metal head , pregnancy ) History schizophrenia , schizoaffective disorder , [ non mood disorder ] psychosis , depression secondary medical condition , mental retardation , substance dependence abuse within past year ( except nicotine ) , bipolar disorder , psychotic feature previous episode , amnestic disorder , obsessive compulsive disorder , posttraumatic stress disorder , panic disorder History autoimmune , endocrine , viral , vascular disorder . Unstable cardiac disease , uncontrolled hypertension , sleep apnea Active suicidal intent plan , history attempt within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Teen</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Depression</keyword>
	<keyword>Transcranial Magnetic Stimulation</keyword>
	<keyword>TMS</keyword>
</DOC>